We combined LATS1/2, CD8, and FOXP3 to analyze the prognoses of advanced GC patients and found that combined analysis of LATS1/2, CD8, and FOXP3 predicted patient prognoses, and the HR of the combined analysis of the three indicators was better than the combination of any two indicators, suggesting that LATS1/2 might play an important role in CD8+ T cells and FOXP3+ Treg cells in a tumor immune microenvironment. This evidence concerns the gene LATS1 and neoplasm.